BioInvent International AB BOVNF
Trading Information
- Previous Close Price
- $4.70
- Day Range
- $3.29–3.29
- 52-Week Range
- $3.29–3.29
- Bid/Ask
- $2.09 / $3.09
- Shares Outstanding
- 65.80M
- Market Cap
- $216.40M
- Volume/Avg
- 463,385 / 463,379
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.86
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 112
- Website
- https://www.bioinvent.com
Valuation
|
Metric
|
BOVNF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.53 |
Price/Sales | 8.86 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BOVNF
|
|---|---|
Quick Ratio | 5.20 |
Current Ratio | 5.32 |
Interest Coverage | — |
Quick Ratio
BOVNF
Profitability
|
Metric
|
BOVNF
|
|---|---|
Return on Assets (Normalized) | −45.54% |
Return on Equity (Normalized) | −52.68% |
Return on Invested Capital (Normalized) | −51.82% |
Return on Assets
BOVNF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|J^lnR! | LOCK|&rH<< | $131B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|kVfGf> | LOCK|!GBk> | $83B | |||
| argenx SE ADR
ARGX
| LOCK|DGP^Wdl | LOCK|!Qk | $54B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|J<gnc^<l | LOCK|j!$Rh | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|C<x#T$< | LOCK|%V | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|J%pc%K< | LOCK|^sFT | $30B | |||
| Moderna Inc
MRNA
| LOCK|<Pp%fR | LOCK|tDf | $25B | |||
| Incyte Corp
INCY
| LOCK|?#X$&T# | LOCK|D^^ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|mF%%$? | LOCK|BL | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!VDGct | LOCK|z^w | $16B |
United States